← Browse by Condition
Medical Condition

metastatic malignant solid neoplasm

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for metastatic malignant solid neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — metastatic malignant solid neoplasm Clinical Trials

How many clinical trials are currently recruiting for metastatic malignant solid neoplasm?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for metastatic malignant solid neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for metastatic malignant solid neoplasm?
metastatic malignant solid neoplasm research spans Phase 1 (4 trials), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a metastatic malignant solid neoplasm clinical trial?
Eligibility criteria for metastatic malignant solid neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
4
Top Sponsors
National Cancer Institute (NCI) 2 trials
M.D. Anderson Cancer Center 2 trials
Mayo Clinic 1 trial
Rahul Aggarwal 1 trial
OHSU Knight Cancer Institute 1 trial

Recruiting Clinical Trials

NCT05564377 Phase 2
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Enrollment
2,900 pts
Location
United States, Puert...
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05691517 Phase 1
Recruiting
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
Enrollment
35 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT04693468 Phase 1
Recruiting
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Enrollment
111 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT05222620 Phase 2
Recruiting
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Enrollment
90 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT04879121 Phase 2
Recruiting
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Enrollment
13 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06942104 Phase 1
Recruiting
Imaging of Solid Tumors Using 18F-TRX
Enrollment
56 pts
Location
United States
Sponsor
Rahul Aggarwal
View Trial →
NCT06320405 Phase 1, Phase 2
Recruiting
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
Enrollment
38 pts
Location
United States
Sponsor
OHSU Knight Cancer Institute
View Trial →

Related Conditions

advanced malignant solid neoplasm (4) recurrent malignant solid neoplasm (3) locally advanced malignant solid neoplasm (2) anatomic stage iii breast cancer ajcc v8 (1) anatomic stage iv breast cancer ajcc v8 (1) malignant female reproductive system neoplasm (1) metastatic her2 negative breast carcinoma (1) recurrent endometrial carcinoma (1) recurrent fallopian tube carcinoma (1) recurrent malignant female reproductive system neoplasm (1) recurrent ovarian carcinoma (1) recurrent primary peritoneal carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology